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Abstract
Background: Mentalization-Based Treatment (MBT) is a promising, though expensive treatment for severely ill patients
with Borderline Personality Disorder (BPD). A high burden of disease in terms of quality of life (QoL) and life years lost
can be a reason to prioritize mental health interventions, and specifically for BPD patients. Moreover, when the societal
costs of the illness are high, spending resources on high treatment costs would be more easily legitimized. Therefore,
the purpose of this study was to calculate the burden of disease of BPD patients eligible for MBT.
Methods: The 403 patients included in this study were recruited from two mental health care institutes in the
Netherlands. All patients were eligible for MBT. Burden of disease consisted of QoL, measured with the EuroQol
EQ-5D-3L, and costs, calculated using the Trimbos and Institute for Medical Technology Assessment Questionnaire for
Costs Associated with Psychiatric Illness.
Results: The mean QoL index score was .48. The mean total costs in the year prior to treatment were €16,879 per
patient, of which 21 % consisted of productivity costs.
Conclusions: The burden of disease in BPD patients eligible for MBT is high, which makes it more likely that
society is willing to invest in treatment for these patients. However, this finding should not be interpreted as a
license to unlimitedly use resources to reimburse treatment for severe BPD patients, as these findings do not
provide any information on the effectiveness of MBT or other available treatment programs for BPD. The effectiveness
of available treatments should be evident by studies on the effectiveness of the treatment itself and by comparing the
effectiveness of these treatments to treatment as usual and to other treatment options for BPD patients.
Trial registration: The data on this paper came from two trials: NTR2175 and NTR2292.
Keywords: Quality of life, Costs, Borderline, Mentalization-based treatment
Background
Borderline personality disorder (BPD) is one of the most
prevalent mental disorders in psychiatric populations [1, 2].
Mentalization-based treatment (MBT) is often the treat-
ment of choice for patients with a severe BPD, as MBT
claims to be able to treat BPD patients situated at the more
severe end of the continuum of severity of pathology [3].
MBT aims to enhance patients’ mentalizing capacity,
particularly in high arousal contexts. Mentalizing refers to
“the mental process by which an individual implicitly and
explicitly interprets the actions of himself and others as
meaningful on the basis of intentional mental states such as
personal desires, needs, feelings, beliefs, and reasons” [4]. In
MBT, impairments in mentalizing are believed to be a core
feature of patients with BPD, and are related to problems
with affect regulation and attentional control. Hence,
improving this capacity is thought to be associated with
a decreased need to rely on maladaptive coping strategies
to deal with feelings of inner emptiness, impulsivity and
conflicts in interpersonal relationships. As a consequence,
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this decreases symptoms and enhances interpersonal
functioning, which is a treatment goal of MBT [4].
Besides being a promising treatment for severely disor-
dered BPD patients, MBT is also considered an expen-
sive treatment, as the treatment intensity is high and
MBT is given by only highly specialized therapists [4].
Given the high costs of treatment, it is warranted to find
evidence to prioritize such an intervention for severe
BPD patients. A high burden of disease in terms of quality
of life (QoL) and life years lost can be a reason to prioritize
health interventions aimed at improving the health status
of these patients [5]. The willingness to pay for such treat-
ment programs tends to be higher than for patients having
less severe health conditions [5]. This relation between
burden of disease and willingness to pay has also
been imbedded in economic theory, usually under the
name ‘equity’ or ‘solidarity’ [6] and is tested in panels
of policy makers and lay people [7–9]. It explains
why we value a small health gain in severely ill pa-
tients higher than the same health gain in patients
with a relatively low burden of disease. For instance, in
the United Kingdom, the willingness to pay ‘thresholds’
for treatments are higher for patients in the last phase of
their life compared to patients who still have a substantial
life expectancy [7]. New standards on cost-effectiveness in
the Netherlands also recognize different thresholds which
are related to the burden of disease: the higher the burden
of disease, the higher the willingness to pay thresholds for
treatments [10], while for example in Belgium, the out of
pocket co-payment of patients is lower when the burden of
disease is higher (http://www.bcfi.be/nl/start). In addition,
people not only tend to put a high value on interventions
for severe health conditions [5], and are more willing to al-
locate resources to treat those patients, they also accept a
higher cost-effectiveness ratio when patients suffer from a
high burden in terms of QoL and costs [5]. Moreover,
when the costs of disease for society are high, it is more
likely that an effective treatment will accomplish cost sav-
ings for society. Thus, for a severely ill patient group, it is
important to estimate their burden of disease, as this bur-
den of disease is a criterion on which to prioritize health
interventions for these patients. The burden of disease is
often presented as QoL and societal costs. For BPD pa-
tients in general, the QoL and societal costs are esti-
mated in some earlier studies, on which we will
elaborate first.
Several studies found that patients with BPD suffer
from a low QoL, as measured with the generic EQ-5D
[11], where the QoL index score as measured with the
EQ-5D is expressed as a single index score, where a
score of 1 represents the value of perfect health, and a
score of 0 represents the value of death. In a Dutch
study the QoL index score was calculated in a sample of
1708 patients with personality disorders (PDs) and it
was estimated to be .52 in BPD patients, representing a
severe burden of disease [12]. Van Asselt and colleagues
[13] performed a randomized controlled trial (RCT) in
BPD patients comparing schema-focused therapy (SFT)
and transference-focused psychotherapy (TFP). They
found baseline QoL index scores of .49 for the SFT group
and .46 for the TFP group. McMain and colleagues [14]
calculated the baseline QoL index score of 180 BPD
patients referred to either dialectical behavior therapy
(DBT) or to general psychiatric management to be .57
and .55, respectively. And though the sample was small,
Bales and colleagues [3] found a QoL index score of .49
in patients allocated to MBT. Moreover, the QoL in
patients with BPD is comparable to that of patients
with severe physical conditions, such as stroke and
Parkinson’s disease (QoL index score of .49 and .44,
respectively) [15, 16] and it is lower than a severe mental
disorder such as major depressive disorder (QoL index
score of .58) [17]. In comparison to the mean QoL index
score of the general population in Western societies,
which ranges between .83 and .87 [18–20], the QoL of
BPD patients is low.
In addition to a low QoL, BPD also causes a high eco-
nomic burden on society. Van Asselt and colleagues [21]
found the total costs per BPD patient to be €16,852 in
the year prior to treatment. Soeteman and colleagues
[22] assessed the economic burden of PDs in 1740
patients with personality pathology. They found the total
cost of patients with a PD in the year prior to treatment
to be estimated at €11,126 per patient. BPD was uniquely
associated with an increased mean total costs. Though not
taking into account the indirect costs due to productivity
losses, such as absence from work or reduced efficiency at
work, Bateman and Fonagy also gave an indication of the
economic burden of patients allocated to MBT [23]. They
estimated the health care utilization costs for BPD patients
receiving psychoanalytically oriented partial hospitalization
in the 6 months before randomization to be $2379 (€2141;
adjusted for inflation and purchasing power parities [24]).
Thus, published evidence presents a low QoL in BPD
patients in general, and high societal costs. However, to
our knowledge, the QoL in BPD patients eligible for
MBT was only estimated in a small sample by Bales [3]
and the costs in BPD patients eligible for MBT was only
estimated by Bateman [23]. More research is clearly
needed, particularly as patients with BPD referred to
MBT tend to be patients situated at the more severe end
of the continuum [3]. The aim of the present study was
therefore to fill this gap of knowledge for these severe
BPD patients. Because of the severity of problems of
these patients, we expected these BPD patients to have
lower QoL and higher costs than other (B)PD patients.
In this study we estimate the burden of disease of BPD
patients eligible for MBT in term of QoL and societal
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costs, by combining baseline data of two RCTs in the
Netherlands.
Methods
Data for this study were collected from two RCTs in the
Netherlands. In the first RCT, called MBT-TAU, Day
Hospital MBT (MBT-DH) was compared to a specialist
Treatment As Usual (S-TAU) and was performed at two
mental health care centres in Amsterdam: Arkin and
De Viersprong [25]. The second RCT, called MBT-
DOS, compared MBT-DH with MBT Intensive Out-
patient treatment (MBT-IOP) and was executed in
Amsterdam (Arkin and De Viersprong), Bergen op
Zoom (De Viersprong) and Groningen (Lentis) [26]. All
treatment centres were specialized in treating BPD pa-
tients. The protocols of both trials were described in
detail elsewhere [25, 26].
Patients
In total, 403 patients were included between March 2009
and July 2014. Patients were included in these studies when
they had a BPD diagnosis as measured by the Structured
Clinical Interview for DSM-IV Axis II Personality Dis-
orders (SCID-II) [27]. In the MBT-TAU study, patients
should also have a total score on the Borderline Personality
Disorder Severity Index (BPDSI) [28] of at least 20,
reflecting severe BPD. Exclusion criteria were: (a) the
presence of an Axis-I disorder (as determined with
the Structured Clinical Interview for DSM-IV Axis I
Personality Disorders (SCID-I) [29] that required spe-
cialist treatment, (b) a diagnosis of autism spectrum
disorders or organic brain disorder that interferes sig-
nificantly with the ability to mentalize; (c) IQ below
80 as measured by the Wechsler Adult Intelligent
Scale–III [30], (d) inadequate mastery of the Dutch
language, and (e) a diagnosis of antisocial personality
disorder in combination with a history of severe phys-
ical violence [25, 26].
Procedure
The SCID-I and SCID-II interviews were administered as
part of the formal admission procedure (De Viersprong)
or to assess whether patients were eligible for the trial
(Arkin and Lentis). If patients fulfilled the inclusion cri-
teria for one of the trials, patients signed informed consent
and were asked to complete a baseline assessment, includ-
ing the EQ-5D-3L and TiC-P measurements. In the MBT-
DOS trial, patients completed the baseline assessment be-
fore randomization. In the MBT-TAU study, patients
completed the baseline assessments partly before and
partly after randomization.
Measures
Axis I and Axis II disorders
Axis I disorders were diagnosed by using the Structured
Clinical Interview for DSM-IV Axis I disorders (SCID-I)
[29, 31]. The Structured Clinical Interview for DSM-IV
Axis II Personality disorders (SCID-II) [27, 32] was used
for diagnosing Axis II personality disorders. Criteria
were scored if they were pathologic, pervasive, persistent
and if they were present for at least 5 years, consistent
with the DSM-IV-TR general diagnostic criteria for the
presence of a personality disorder [33].
Symptoms
The Dutch version of the Brief Symptom Inventory (BSI)
[34, 35] was used to assess general psychopathological
symptoms. The BSI is the short version of the Symptom
Checklist-90. It includes 53 items covering nine symptom
dimensions (somatization, obsession-compulsion, inter-
personal sensitivity, depression, anxiety, hostility, phobic
anxiety, paranoid ideation and psychoticism) and yields
three global indices of distress: Positive Symptom Distress
Index, Positive Symptom Total, and Global Severity
Index (GSI). Possible GSI scores range from 0 to 4, with
higher scores indicating a higher level of psychological
and emotional distress. Respondents have to rate each
item (e.g. “your feelings are easily hurt”) on a five-point
scale ranging from 0 (not at all) to 4 (extremely), repre-
senting the intensity of distress relating to each item
during the past 7 days. The reliability of the Dutch ver-
sion of the BSI is good (Cronbach’s α ranging from .71
to .88, test-retest reliability ranging from r = .71 to .89).
These values are comparable to the original BSI version
of Derogatis [34].
Quality of life
QoL was measured using the EuroQol EQ-5D-3L [36].
This self-report questionnaire provides a simple method
to measure health problems in 5 dimensions: mobility,
self-care, usual activities, pain/discomfort and anxiety/
depression. Each dimension is divided into three response-
levels: no problem, moderate problems, and extreme prob-
lems. Combining these scores gives 243 possible health
states, where each of these is weighted to obtain a single
index score between -.33 (worst imaginable health state)
and 1 (best imaginable health state) [37]. A score of 1 rep-
resents the value of perfect health, whereas a score of 0
represents the value of death. Sometimes patients
experience extreme problems on all five dimensions,
which can turn their QoL index score below zero.
However, normally this state is temporary [38]. To
calculate the mean QoL index score, we used norm scores
of a Dutch validation study [37]. The QoL index score is
thus estimated based on the preferences of the Dutch gen-
eral public and represents a value the public would assign
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to the measured health state [39]. The reliability of the EQ-
5D-3L has been investigated and found to be acceptable
[40] and it has shown to be sensitive to change in patients
with personality disorders [22, 41].
Costs
The direct costs (e.g. increased health care utilization) and
indirect costs (e.g. productivity losses due to disability and
to higher absence from work) in the year prior to treat-
ment were assessed using the Trimbos and Institute for
Medical Technology Assessment Questionnaire for Costs
Associated with Psychiatric Illness (TiC-P) [42, 43]. The
first part of the TiC-P consists of questions on (1) the
number of visits to, e.g. a general practitioner, psychiatrist
(outside the treatment offered in the trials), medical spe-
cialist, physiotherapist or alternative health practitioner;
(2) the day care/hospital lengths of stay (outside treatment
offered in the trials); and (3) the use of medication in the
4 weeks prior to the administration of the questionnaire
in MBT-DOS and 6 months in MBT-TAU [42]. These
care and cure volumes were multiplied with unit prices of
the corresponding health care services according to the
Dutch manual for costing studies in health care [44].
The unit prices for 2010 will be adjusted to 2014 prices
using the Consumer Price Index [45]. Both recall times
(4 weeks in MBT-DOS and 6 months in MBT-TAU) were
standardized to 1 year.
The second part of the TiC-P asks the patient to re-
port absence from work, reduced efficiency at work and
difficulties with nonpaying jobs. The days of short-term
absence from work and actual hours missed at work due
to health-related problems were multiplied with the
average productivity costs per employee per hour,
taking into account the number of days and hours of paid
employment of the patient per week. Because the recall
period of this part of the TiC-P was 2 weeks, we multi-
plied the costs by 26 to estimate the annual costs. To
value long-term absence from work, we applied the fric-
tion cost method [22, 46, 47]. This method takes the
employer's perspective, and counts as lost only those
hours not worked until another employee takes over the
patient's work. This period, the so-called friction period, is
estimated to be 116 days. Hence, the maximum indirect
costs were limited to productivity losses during 116 days.
The friction cost method is a more conservative estimate
than the so-called “human capital method”, which relates
productivity costs one-to-one to the labour costs of the
patient. The choice between friction costs and human
capital is still a subject of debate among economists
[22, 46, 47]. Furthermore, difficulties with non-paying
jobs were estimated as hours a patient was supported
in for example housekeeping activities, and was multi-
plied with the corresponding unit prices [42, 43].
Burden of disease
We estimated the burden of our patient population in
terms of their QoL and direct and indirect costs, which
represent the societal costs of these patients. In addition,
we described their socio-demographic and diagnostic
data and GSI scores. We reported the mean and standard
deviation of the QoL index score, the direct and indirect
costs, and the GSI score.
Results
Participants
Table 1 presents the social demographic and diagnostic
data at baseline. As can be expected, the majority of the
sample was female (82 %). The majority (81 %) of the
patients had at least one co-occurring Axis-I disorder
and 41 % had at least one co-occurring Axis-II disorder.
The mean GSI score at baseline was 1.92 (SD = .79);
representing a high level of psychological and emotional
distress.
Burden of disease: quality of life and costs
The mean QoL index score in our patient population
was .48 (SD = .29), representing a severe burden of disease
(Table 1). Table 2 describes the direct and indirect costs in
the year prior to treatment. The mean total direct costs
Table 1 Sociodemographic and diagnostic data
Number Percent Valid N Missing
Gender (Male) 71 17.6 403 0
Self-harm in the past 6 months 150 45.2 332 71
Suicide attempt in the past
6 months
125 37.3 335 68
Co-morbid Axis I disorders
Anxiety disorder 184 46.6 395 8
Mood disorder 229 57.8 396 7
Pychotic disorder 16 4.0 396 7
Eating disorder 90 22.7 396 7
At least 1 co-morbid
Axis I disorder
320 80.8 396 7
Co-morbid Axis II disorders
Avoidant PD 62 15.4 403 0
Obsessive compulsive PD 24 6.0 403 0
Histroic PD 2 .5 403 0
Narcissictic PD 10 2.5 403 0
At least 1 co-morbid
Axis II disorder
164 40.7 403 0
Mean SD Valid N Missing
Age 31.37 9.47 344 59
QoL index score .48 .29 316 87
GSI score 1.92 .79 335 68
QoL index score Quality of Life index score, GSI Global Severity Index
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per patient were €13,405 per year. Those costs were
mainly composed of costs due to inpatient health care
(39.1 %), outpatient mental health care (18.6 %) and
day hospital care (14 %). The total mean indirect costs
per patient were €3474 per year. Here, absence from
work and reduced efficiency at work were estimated for
the 90 patients (28.1 % of 320 valid N; 83 missing
values) that had a paying job. These patients reported
the total hours lost to be 101.34 (Table 2). The mean
total costs of BPD patients were €16,879 per year.
Discussion
BPD patients eligible for MBT reported a severe QoL
and were accountable for high costs on society. The
main cost drivers were inpatient mental health care, out-
patient mental health care and absence from work.
The QoL in our sample seems lower or at least compar-
able to patients with severe physical and mental illnesses,
for example diabetes (QoL index score of .62) [15], asthma
(QoL index score of .67) [15], ischaemic heart disease
(QoL index score of .55) [15], chronic pain with neuro-
pathic characteristics (QoL index score of .47) [48], Par-
kinson’s disease (QoL index score of .44) [16] and major
depressive disorder (QoL index score of .58) [17]. The
mean QoL index score in our sample is also comparable
to the QoL index score in BPD patients estimated in other
studies, with QoL index score ranging from .46 to .57 [3,
12–14]. This result is in contrast to our expectation that
BPD patients eligible for MBT patients would have lower
QoL than other (B)PD patients.
The economic burden of BPD patients eligible for
MBT seems considerably higher than the burden of pa-
tients seeking mental health treatment for other mental
and physical disorders, such as anxiety disorders, mood
disorders and Parkinson’s disease, which cost €1077,
€3406 and €11,153 per patient per year respectively [49].
The economic burden in our trial is comparable to the
costs of psychotic disorders: €18,796 [49] and to two
other studies on costs of PDs and BPD: €11,126 per
Table 2 Mean costs per year of patients with BPD








Valid N Missings Subjects using the
service, (% of valid N)
Direct medical costs per year
General practitioner 10.16 312.70 636.93 2.3 141 322 81 43.8
Company doctor 2.07 63.56 163.38 .5 56 308 95 18.2
Physiotherapist 3.54 140.26 644.45 1.0 30 317 86 9.5
Alternative health practitioner 2.15 116.45 772.13 .9 21 320 83 6.6
Domestic help 44.34 704.33 3235.95 5.3 47 339 64 13.9
Self help group 4.7 271.76 1732.54 2.0 19 315 88 6.0
Social worker 3.55 253.46 960.62 1.9 47 315 88 14.9
Substance abuse
outpatient care
1.29 39.53 286.92 .3 18 319 84 5.6
Outpatient mental
health care
13.24 2488.36 5589.44 18.6 113 288 115 39.2
Psychiatric practice 9.8 947.85 2175.99 7.1 95 296 107 32.1
Outpatient clinic 2.84 359.08 1453.43 2.7 36 310 93 11.6
Day hospital care 10.39 1880.12 6779.94 14.0 44 314 89 14.0
Inpatient health care 11.4 5239.60 27586.25 39.1 28 314 89 8.9
Medical specialist 1.94 153.48 510.58 1.1 41 313 90 13.1
Medication NA 434.48 634.35 3.2 82 109 294 75.2
Total 13405.00
Indirect costs per year
Absence from worka 84.14 2502.54 10005.20 72.0 41 317 86 12.9
Reduced efficiency
at worka
17.3 467.24 2951.80 13.4 16 283 120 5.7
Difficulties with
nonpaying jobs
36.73 504.63 1466.64 14.5 44 241 162 18.3
Total 3474.41
NA Not Applicable
aEstimated for 90 patients that had a paying job (320 valid N; 83 missing values)
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patient in the study by Soeteman [22] and €16,205 in pa-
tients with BPD per year in the study by Van Asselt and
colleagues [21]. The costs that Bateman and Fonagy cal-
culated in the 6 months before randomization were
$2379; when adjusted for inflation and purchasing power
parities, costs per person per year were approximately
€2141 [24]. These costs are substantially lower than the
total costs in our trial, which is probably due to the exclu-
sion of indirect costs in their analyses [23]. Wagner and
colleagues [50] calculated that in the year prior to dialect-
ical behavior therapy, BPD patients had a total mean an-
nual societal cost of €28,026 per patients. This is more
than €10,000 higher than the societal costs we found in
our study (€16,879). This difference could be explained by
using a different method to estimate productivity losses.
Wagner and colleagues used the Human Capital Ap-
proach (HCA) [51], whereas we used the Friction Cost
Method [52]. Using the HCA, it is assumed that product-
ivity losses last until the age of retirement or until the time
the person has found an equivalent job. The friction cost
method estimates productivity losses in a more conserva-
tive manner by using the time needed to replace a worker.
This method is believed to result in actual productivity
costs, whereas HCA is criticized for calculating potential
rather than actual productivity costs, leading to unrealis-
tically high estimates of productivity costs [22, 53]. The
finding that the costs in our patient population was com-
parable to other BPD patients and other PD populations
was not in line with our expectations; we expected severe
BPD patients eligible for MBT to report higher societal
costs than other patient populations.
Strengths and limitations
One of the strengths of this study is the use of a generic
QoL measure, which made it possible to compare the
QoL index score of the BPD patients in our study to that
of patients with other mental and physical illnesses.
Although it is suggested that the EQ-5D-3 L may not be
sensitive enough to reflect the impact of severe mental
disorders, such as chronic schizophrenia and PDs [54], the
current study showed that these concerns are not justified
for severe BPD patients in our study population. We
found a severely disturbed QoL in these patients,
which indicated that an important part of the
problems in this particular patient group was well
captured with the EQ-5D-3 L. In addition, other studies
on QoL in BPD patients found similar QoL index scores,
indicating the robustness of the present findings [12, 55].
A second strength was the use of an extensive cost
questionnaire, by which we could calculate both direct
and indirect costs. Bateman and Fonagy only estimated
direct costs, and did not take into account the indirect
costs due to productivity losses [23]. The current study
now added those costs to the total costs of patients eli-
gible for MBT, and made costs comparable to other stud-
ies on the economic burden of PD in general and BPD
specifically.
We only included BPD patients eligible for MBT,
which may limit the generalizability of our study re-
sults to the general group of BPD patients. However,
our results showed that societal costs and QoL were
comparable to other studies on QoL and costs in
BPD patients. A second limitation is the considerable
number of missing data, especially in the cost data,
as can be seen in Table 2. We mostly missed data
from the RCT that aimed to compare MBT-DH with
S-TAU. This could be explained by the procedure of mea-
surements. Only the SCID-II and the BPDSI were calcu-
lated for all patients before randomization as part as the
admission procedure for this study. The other baseline
measures were administered after randomization, including
the EQ-5D-3L, TiC-P and BSI. As a lot of the S-TAU pa-
tients were unhappy with their treatment allocation, many
of these patients refused to complete the test battery after
randomization. Though other studies on costs in BPD pa-
tients do not mention missing data [21–23], we know out
of personal communication that the study by Soeteman
also had a considerable number of missing data. Despite
the missing data in our trial, the QoL and EQ-5D score
were still within the same range as these earlier studies.
Missing data influences, however, the costs estimates as
presented in Table 2. On the one hand, the patients whose
costs were unknown could have had a high amount of
health- related costs, such that the overall estimated costs
represent an underestimation. On the other hand, it is pos-
sible that these patients had no costs at all. In that case, the
estimated costs in this study could be overestimated, be-
cause we only represented the costs of those patients that
actually filled in the cost questionnaire. A third limitation
relates to the measurement of costs by self-report. The
costs were not based on more objective sources such as
data from health insurance companies, which may have led
to an underestimation of costs. However, self-report was
commonly used to calculate costs on BPD patients in earl-
ier studies, and to our knowledge, there are no studies
using data from health insurance companies yet. In
addition, data from health insurance companies is limited
to costs covered by the health insurance and has no
information on, for example, out of pocket costs. A fifth
limitation is that we calculated the costs prior to start of
treatment. These costs may be very high, because
patients had severe problems, for which they eventu-
ally received treatment. On the other hand, it is also
possible that costs prior to treatment are lower than
usual, because patients know they will receive treat-
ment and therefore don’t make use of other
resources.
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Practical implications
Our study showed a high burden of disease in BPD pa-
tients eligible for MBT. This high burden can help priori-
tizing health interventions for severely ill BPD patients
in general, and MBT specifically, as people tend to be
willing to pay more to treat patients with a higher bur-
den of disease. Given the low QoL and high societal
burden we found in this study, an expensive treatment
for severely ill BPD patients, such as MBT, can more
easily be legitimized. However, as the burden of disease
in severe BPD patients is comparable to the burden of
other BPD patients and patients with other PDs,
prioritization of resources for severe BPD patients
based on (cost)-effectiveness research becomes even
more important. Though an expensive treatment is
more easily legitimized, our results provide no license
to unlimitedly use resources to reimburse MBT or
other highly specialized treatments for severe BPD pa-
tients, as these findings do not provide any information
on the (cost-)effectiveness of available treatment pro-
grams. The effectiveness of treatment programs should
be evident, not only by studies on the effectiveness of
the treatment itself, but also by comparing the effect-
iveness of MBT to TAU and to other highly specialized
treatments for BPD patients. Although there is some
promising evidence supporting the effectiveness of
MBT-DH and MBT-IOP [3, 56–58], given the small
number of studies, more research is urgently needed, par-
ticularly in light of the limitations of existing trials. These
include possible researcher allegiance, questions about
generalizability and the lack of a credible TAU. Moreover,
more research into the effectiveness of other specialized
treatments for BPD, such as SFT and DBT, is also war-
ranted. Various studies show that the effectiveness of
these highly specialized treatments seems comparable
to well-specified treatments for BPD that are delivered
in a consistent, coherent and continuous way [59–61].
As a result, in practice, integrative treatments are already
being developed [62], combining the best of specialist
techniques and common factors. Yet, research on the
effectiveness of these integrated treatments is needed.
Furthermore, when for example MBT turns out to be
more effective, but also more costly than the intervention
to which it would be compared, a cost-effectiveness analysis
of MBT is needed to estimate the cost-effectiveness ratio of
MBT compared to alternative treatment options. Currently,
we are comparing day hospital MBT to specialist TAU [25]
on its effectiveness and costs. At the same time, two inten-
sities of MBT, day-hospital MBT [56] and intensive out-
patient MBT [57], are compared on effectiveness and costs
[26]. Cost-effectiveness analyses can support the reimburse-
ment decision in which treatment should be paid for.
However, a cost-effectiveness analysis is not the only tool
to decide on this. The burden of disease is also an
important criteria to decide which treatment should be
paid for, and can yield a strong argument in favor of reim-
bursing treatments for severely ill BPD patients.
Conclusions
Given the low QoL and high societal burden we found
in this study, it can be more easily legitimized to treat
severely ill BPD patients with an expensive treatment
such as MBT. However, more research is needed on the
(cost)-effectiveness of specialist treatments for BPD such
as MBT versus TAU, integrated treatments and other
specialist treatments for BPD, as the findings from this
study do not provide any information on the effective-
ness of available treatment programs.
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